TipRanks
Go Ultimate55% OFF

Akso Health Group Sponsored ADR (8HX) AI Stock Analysis

DE:8HX

Akso Health Group Sponsored ADR

(Frankfurt:8HX)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Revenue GrowthThe company has demonstrated substantial revenue growth, indicating strong market demand and successful expansion efforts in healthcare services.
Negative Factors
Profitability ChallengesSevere profitability issues due to net losses undermine financial health, necessitating strategic changes to improve cost efficiency and revenue generation.

Akso Health Group Sponsored ADR (8HX) vs. iShares MSCI Germany ETF (EWG)

-75%-50%-25%0%25%50%75%DE:8HX-17.78%EWG+6.61%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
Market Cap
EUR 1.12B
Dividend Yield
―
Average Volume (3M)
―
Price to Earnings (P/E)
-19.5
Beta (1Y)
0.31
Revenue Growth
-13.36%
EPS Growth
95.68%
Country
Germany
Employees
12
Sector
Healthcare
Sector Strength
51
Industry
Medical - Distribution

Akso Health Group Sponsored ADR Business Overview & Revenue Model

Company Description

Akso Health Group, together with its subsidiaries, operates a social e-commerce mobile platform in the People’s Republic of China. It operates Xiaobai Maimai App, a social e-commerce mobile platform that offers food and beverage products, wine, cosme...

Akso Health Group Sponsored ADR Risk Analysis

Akso Health Group Sponsored ADR disclosed 82 risk factors in its most recent earnings report. Akso Health Group Sponsored ADR reported the most risks in the "Legal & Regulatory" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

0 New Risks

Akso Health Group Sponsored ADR Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:8HX against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
FINVFINV76Outperform$688.51M2.524.56%10.41%-1.89%-26.81%
LXLX62Neutral$102.34M0.728.64%57.36%-4.17%-34.34%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
FOAFOA47Neutral$266.66M-30.42-0.10%―-2.88%-104.13%
YRDYRD37Underperform$36.26M-0.16-16.95%48.18%-27.36%-220.29%

* Healthcare Sector Average

Performance Comparison

-50%0%50%DE:8HXYRDFINVLXFOADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
DE:8HX and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:8HXAkso Health Group Sponsored ADR1.11-0.24-17.78%
YRDYiren Digital Ltd. Sponsored Adr0.41-5.01-92.38%
FINVFinvolution Group2.94-2.71-47.93%
LXLexinfintech0.67-3.40-83.62%
FOAFinance Of America Companies Inc10.95-10.99-50.09%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.